Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia

Blood (2024) 144 (Supplement 1): 3205.

https://doi.org/10.1182/blood-2024-204557

Published: 2024

Journal Articles

Prognostic Impact of Complex Karyotype in Acute Promyelocytic Leukemia

Julia Ribes-Amoros, Helena Pomares, Susana Vives, Nuria Brey, Jordi Verge, Rosa Coll, Marta Cervera, Elena Bechtold Javier, Shiomara Quiñones, Maria Isabel Sotelo, Mercedes Galiano, Esther Alonso, Anna Sureda Balari, Lurdes Zamora, Isabel Granada, Montserrat Arnan

Blood (2024) 144 (Supplement 1): 6138.

https://doi.org/10.1182/blood-2024-205868

Published: 2024

Journal Articles

Impact of Transfusion Dependency on Patients Diagnosed with Myelodysplastic Syndrome According to IPSS-M Risk Group

Blood (2024) 144 (Supplement 1): 1838.

https://doi.org/10.1182/blood-2024-205407

Published: 2024

Journal Articles

SF3B1 Mutation Significance in Myeloid Neoplasms without Anemia

Blood (2024) 144 (Supplement 1): 6710.

https://doi.org/10.1182/blood-2024-206109

Published: 2024

Journal Articles

Clinical Characteristics of Patients with TP53 Multihit MDS and AML. a Single-Center Experience

Jasson Villarreal Hernandez, Helena Pomares, Antonella Sturla, Esther Alonso, Clara Maluquer Artigal, Rebecca Andersson, María Alicia Senin, Maria Teresa Encuentra, Mercedes Galiano, Lurdes Zamora, Marta Cabezón, Neus Ruiz Xiville, Maria Carolina Florian, Anna Maria Sureda Balari, Montserrat Arnan Sangerman

Blood (2023) 142 (Supplement 1): 5868.

https://doi.org/10.1182/blood-2023-187430

Published: 2023

Journal Articles

Retrospective Single Center Descriptive Analysis of a Cohort with Hypereosinophilia Evaluated in the Last Decade

Blood (2023) 142 (Supplement 1): 6425.

https://doi.org/10.1182/blood-2023-184980

Published: 2023

Journal Articles

Validation of Low Risk Prognostic Scoring System (LR-PSS) in Patients with Lower Risk IPSS-R Myelodysplastic Syndrome. Results from a Single Center

Montserrat Arnan Sangerman, MD PhD, Helena Pomares, MD PhD, Esther Alonso, MD, Mercedes Galiano, Maite Encuentra, Javier Grau, MD PhD, Anna Sureda, MD PhD

Blood (2019) 134 (Supplement_1): 4270.

https://doi.org/10.1182/blood-2019-127901

Published: 2019

Journal Articles

Acute Myeloid Leukemia with Myelodisplasia-Related Changes (AML-MRC) Defined Only By Morphological Findings May Not Represent a Poor Prognosis AML

Blood (2019) 134 (Supplement_1): 2612.

https://doi.org/10.1182/blood-2019-129153

Published: 2019

Journal Articles

Impact of Red Blood Cell Transfusion Burden Status in Patients with Lower-Risk Myelodysplastic Syndromes

Montserrat Arnan Sangerman, Helena Pomares, MD PhD, Esther Alonso, MD, Javier Grau, MD PhD, Mercedes Galiano, Maite Encuentra, Anna Sureda, MD PhD

Blood (2019) 134 (Supplement_1): 3013.

https://doi.org/10.1182/blood-2019-127486

Published: 2019

Journal Articles

Percentage of Erythroid Cells in Bone Marrow at Diagnosis As a New Prognostic Factor in Patients with Myelodysplastic Syndrome

Blood (2018) 132 (Supplement 1): 4363.

https://doi.org/10.1182/blood-2018-99-110210

Published: 2018

Journal Articles

Prognostic VALUE of EARLY Drop in the Platelet Counts in Patients with VERY Low, Low and Intermediate Risk IPSS-R Myelodysplastic Syndromes. Results from a Single Center Analysis

Helena Pomares, Isabel Sánchez-Ortega, MD PhD, Javier Grau, MD PhD, Esther Alonso, Maite Encuentra, Anna Sureda, Montserrat Arnan Sangerman

Blood (2017) 130 (Supplement 1): 2968.

https://doi.org/10.1182/blood.V130.Suppl_1.2968.2968

Published: 2017

Journal Articles

An IPSS-R Cutpoint of 3 Stratified Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) Patients (pts) into Two Risk Groups

Julia Montoro, Helena Pomares, Brayan Merchan, Antonieta Molero, Silvia Saumell, Esther Alonso, Mónica Fernández, Laura Gallur, Javier Grau, Olga Salamero, Adoración Blanco, Anna Varela, Elisa Roldán, Anna Sureda, Francesc Bosch, Montserrat Arnan Sangerman, David Valcarcel

Blood (2017) 130 (Supplement 1): 5306.

https://doi.org/10.1182/blood.V130.Suppl_1.5306.5306

Published: 2017

Journal Articles

Considering Bone Marrow Blasts from Nonerythroid Cellularity Improves the Prognostic Evaluation of MDS in the Context of IPSS-R and Permits a Better Risk Assessment of MDS Patients Classified into the Intermediate Risk Category

Blood (2016) 128 (22): 3185.

https://doi.org/10.1182/blood.V128.22.3185.3185

Published: 2016

Journal Articles

Myelodysplastic Syndromes (MDS) with Erythroid Hyperplasia: Enumerating Blasts from Non-Erythroid Cell Compartment Improves the Risk Stratification of MDS with Excess of Blasts

Leonor Arenillas, MD, Xavier Calvo, MD, Mar Tormo, MD PhD, David Valcárcel, MD PhD, Elisa Luño, MD PhD, Esther Alonso, MD, María Consuelo Cañizo, MD PhD, Fernando Ramos, MD PhD MPH, Carmen Pedro, MD PhD, Beatriz Arrizabalaga, MD, Alicia Bailén, MD, José María Raya, MD, María Teresa Ardanaz, MD, Guillermo Sanz, MD PhD, Lourdes Florensa, MD PhD

Blood (2015) 126 (23): 2894.

https://doi.org/10.1182/blood.V126.23.2894.2894

Published: 2015

Journal Articles

Validation of the Low Risk Prognostic Scoring System (LR-PSS) in Patients with VERY Low, Low and Intermediate Risk IPSS-R Myelodysplastic Syndrome. Results from a Single Center

Helena Pomares, MD, Isabel Sánchez-Ortega, MD PhD, Esther Alonso, MD, Javier Grau, MD, Rafael F. Duarte, MD PhD, Anna Sureda, MD PhD, Montserrat Arnan, MD PhD

Blood (2015) 126 (23): 2902.

https://doi.org/10.1182/blood.V126.23.2902.2902

Published: 2015

Journal Articles

RAEB-1 with Erythroid Hyperplasia and Erythroleukemia Share Clinico-Biological Features and Outcome: A Same Disease with Different Labels?

Xavier Calvo, MD, Leonor Arenillas, MD, Mar Tormo, MD PhD, David Valcárcel, MD PhD, Elisa Luño, MD PhD, Esther Alonso, MD, María Díez-Campelo, MD PhD, Fernando Ramos, MD PhD MPH, Carmen Pedro, MD PhD, Beatriz Arrizabalaga, MD, Alicia Bailén, MD, José María Raya, MD, María Teresa Ardanaz, MD, Guillermo Sanz, MD PhD, Lourdes Florensa, MD PhD

Blood (2015) 126 (23): 2866.

https://doi.org/10.1182/blood.V126.23.2866.2866

Published: 2015

Journal Articles

Clinical and Biological Characteristics According to the Burden of JAK2V617F Mutated Allele in BCR-ABL Negative MPNs

Blood (2012) 120 (21): 1437.

https://doi.org/10.1182/blood.V120.21.1437.1437

Published: 2012

Journal Articles

Multilineage Dysplasia Confers Poor Prognosis to Patients with De Novo Acute Myeloid Leukemia with Intermediate-Risk Cytognetics and Wild-Type NPM1 .

Jose Tomas Navarro, MD; PhD, Maria Rozman, MD, PhD, Leonor Arenillas, Ana Aventin, Teresa Gimenez, MD, Esther Alonso, MD, PhD, Granada Perea, MD; PhD, Mireia Camós, MD, PhD, Mayda Navarrete, MD, Esperanza Tuset, MD, Lourdes Florensa, MD, Fuensanta Millá, MD, PhD, Josep F Nomdedeu, MD, Esmeralda de la Banda, MD, Marina Díaz-Beyá, MD, Salut Brunet, Jorge Sierra, MD, PhD, Jordi Esteve, MD, PhD

Blood (2012) 120 (21): 2551.

https://doi.org/10.1182/blood.V120.21.2551.2551

Published: 2012

Journal Articles

AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells

Antonio F. Santidrián, Diana M. González-Gironès, Daniel Iglesias-Serret, Llorenç Coll-Mulet, Ana M. Cosialls, Mercè de Frias, Clara Campàs, Eva González-Barca, Esther Alonso, Verena Labi, Benoit Viollet, Adalberto Benito, Gabriel Pons, Andreas Villunger, Joan Gil

Blood (2010) 116 (16): 3023–3032.

https://doi.org/10.1182/blood-2010-05-283960

Published: 2010

Includes: Supplemental data

Journal Articles

AICAR Induces Apoptosis in Chronic Lymphocytic Leukemia Cells through the Mitochondrial Pathway and Independently of p53 Pathway and AMPK Activation.

Joan Gil, PhD, Antonio F Santidrián, PhD, Diana M González-Gironès, PhD, Daniel Iglesias-Serret, PhD, Llorenç Coll-Mulet, PhD, Ana M Cosialls, PhD, Mercè de Frias, PhD, Clara Campàs, PhD, Eva González-Barca, MD, PhD, Esther Alonso, MD, Alberto Fernandez de Sevilla, MD, PhD, Benoit Viollet, PhD, Gabriel Pons, MD, PhD

Blood (2009) 114 (22): 4819.

https://doi.org/10.1182/blood.V114.22.4819.4819

Published: 2009

NARROW

Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia

Prognostic Impact of Complex Karyotype in Acute Promyelocytic Leukemia

Impact of Transfusion Dependency on Patients Diagnosed with Myelodysplastic Syndrome According to IPSS-M Risk Group

SF3B1 Mutation Significance in Myeloid Neoplasms without Anemia

Clinical Characteristics of Patients with TP53 Multihit MDS and AML. a Single-Center Experience

Retrospective Single Center Descriptive Analysis of a Cohort with Hypereosinophilia Evaluated in the Last Decade

Validation of Low Risk Prognostic Scoring System (LR-PSS) in Patients with Lower Risk IPSS-R Myelodysplastic Syndrome. Results from a Single Center

Acute Myeloid Leukemia with Myelodisplasia-Related Changes (AML-MRC) Defined Only By Morphological Findings May Not Represent a Poor Prognosis AML

Impact of Red Blood Cell Transfusion Burden Status in Patients with Lower-Risk Myelodysplastic Syndromes

Percentage of Erythroid Cells in Bone Marrow at Diagnosis As a New Prognostic Factor in Patients with Myelodysplastic Syndrome

Prognostic VALUE of EARLY Drop in the Platelet Counts in Patients with VERY Low, Low and Intermediate Risk IPSS-R Myelodysplastic Syndromes. Results from a Single Center Analysis

An IPSS-R Cutpoint of 3 Stratified Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) Patients (pts) into Two Risk Groups

Considering Bone Marrow Blasts from Nonerythroid Cellularity Improves the Prognostic Evaluation of MDS in the Context of IPSS-R and Permits a Better Risk Assessment of MDS Patients Classified into the Intermediate Risk Category

Myelodysplastic Syndromes (MDS) with Erythroid Hyperplasia: Enumerating Blasts from Non-Erythroid Cell Compartment Improves the Risk Stratification of MDS with Excess of Blasts

Validation of the Low Risk Prognostic Scoring System (LR-PSS) in Patients with VERY Low, Low and Intermediate Risk IPSS-R Myelodysplastic Syndrome. Results from a Single Center

RAEB-1 with Erythroid Hyperplasia and Erythroleukemia Share Clinico-Biological Features and Outcome: A Same Disease with Different Labels?

Clinical and Biological Characteristics According to the Burden of JAK2V617F Mutated Allele in BCR-ABL Negative MPNs

Multilineage Dysplasia Confers Poor Prognosis to Patients with De Novo Acute Myeloid Leukemia with Intermediate-Risk Cytognetics and Wild-Type NPM1 .

AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells

AICAR Induces Apoptosis in Chronic Lymphocytic Leukemia Cells through the Mitochondrial Pathway and Independently of p53 Pathway and AMPK Activation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only